(Epilepsy research[TA])
5,826 results
  • Efficacy of Lactobacillus reuteri as an adjunctive therapy for seizure control and quality of life in pediatric drug-resistant epilepsy: A prospective interventional study. [Journal Article]
    Epilepsy Res. 2026 Oct 15; 228:107936. [Online ahead of print]Abbasi E, Ghazavi A, … Rasouli JER
  • CONCLUSIONS: In this single-arm before-after study, statistically significant within-participant changes in HRQOL and seizure frequency were observed during the 12-week period following adjunctive L. reuteri supplementation. However, the absolute magnitude of these changes was modest and their clinical significance remains uncertain. Because there was no concurrent placebo control group, the observed changes cannot be attributed specifically to L. reuteri supplementation. Larger, adequately powered placebo-controlled randomized trials are needed to determine whether L. reuteri provides a clinically meaningful benefit in pediatric drug-resistant epilepsy.
  • Response to: "Early benzodiazepine treatment and electrographic seizures after febrile status epilepticus". [Letter]
    Epilepsy Res. 2026 Oct 06; :107931. [Online ahead of print]Souma K, Yamaguchi H, … Nishiyama MER
  • We appreciate Inui et al.'s comments regarding the divergent prognostic outcomes of patients with electrographic seizures (ESz) between our studies. The poorer prognosis in their cohort compared to ours likely stems from three key differences. First, baseline disease severity significantly differed. Our cohort predominantly consisted of milder cases, such as febrile seizures, with only 17.2% requ…
  • Impact of Ramadan on seizure-related emergency department visits in Qatar. [Journal Article]
    Epilepsy Res. 2026 Sep 29; 228:107929. [Online ahead of print]Zammar K, Rizwan H, … Haddad NER
  • CONCLUSIONS: Ramadan was not associated with increased seizure-related ED burden. Emergency physicians modified acute management for fasting subjects by favouring intravenous antiseizure medication loading and deferring new oral regimen initiation.
  • Intrathecal dexamethasone in FIRES. [Review]
    Epilepsy Res. 2026 Sep 23; 228:107924. [Online ahead of print]Foong WD, Tan Z, … Tan YJER
  • CONCLUSIONS: IT-DEX may represent a promising therapeutic option for FIRES, particularly in children and adolescents. Our findings provide preliminary evidence supporting its potential use, with administration at 72-hour intervals to a cumulative dose of 1 mg/kg emerging as a potentially reasonable approach. However, further studies are required to determine its optimal dosing, safety and efficacy.
  • Beyond the classic ketogenic diet: A systematic review of alternative and adjunctive therapies for GLUT1 deficiency syndrome. [Review]
    Epilepsy Res. 2026 Sep 23; 228:107926. [Online ahead of print]Falsaperla R, Ben Amer S, Sortino VER
  • CONCLUSIONS: While CKD remains the reference standard for GLUT1-DS management, selected alternative and adjunctive therapies may offer clinically meaningful benefit in specific clinical contexts. The current evidence base, however, is limited. These findings support cautious and individualized use of alternative therapeutic strategies while highlighting the need for larger prospective studies and standardized outcome measures to better define their role in GLUT1-DS management.